Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
F-18 DPA-714 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| F-18 DPA-714 (BAY85-8102) | DRUG | Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT |
Inclusion Criteria: * Able to give fully informed consent in writing * Males or females aged \>/= 50 years * No significant disease or drug use * Absence of any sign of dementia/cognitive impairment in neuropsychological examinationsPatients for brain imaging: * Patient and designee capable of givi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Hologic, Inc. | HOLX | 1 | N/A | Undisclosed |
| Intelligent Bio Solutions Inc. | INBS | 1 | - | Undisclosed |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
| GE Healthcare Technologies Inc. | GEHC | 2 | N/A | Undisclosed |
F-18 DPA-714 is a small molecule diagnostic imaging agent in clinical development for use in diagnostic imaging. It is being studied to evaluate neuroinflammation patterns in patients with probable Alzheimer's disease compared to healthy volunteers, as well as for radiation dosimetry in healthy volunteers.
F-18 DPA-714 is being developed by Bayer AG, a company traded under the ticker BAYRY. The drug is currently in Phase 1 clinical development for diagnostic imaging applications.
F-18 DPA-714 is in Phase 1 clinical development. It is an investigational diagnostic imaging agent and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 22 participants.
F-18 DPA-714 has one completed clinical trial, NCT01009359, which evaluated the neuroinflammation pattern of BAY85-8102 F-18, DPA-714 in probable Alzheimer's disease patients versus healthy volunteers, and radiation dosimetry in healthy volunteers. The trial enrolled 22 participants in Finland and the Netherlands.
Yes, F-18 DPA-714 is also known as BAY85-8102. The clinical trial NCT01009359 refers to the drug as BAY85-8102 F-18, DPA-714, confirming that these names refer to the same investigational diagnostic imaging agent.